{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T15:28:17Z","timestamp":1791300497145,"version":"4.1.0"},"reference-count":34,"publisher":"Oxford University Press (OUP)","issue":"5","license":[{"start":{"date-parts":[[2017,3,14]],"date-time":"2017-03-14T00:00:00Z","timestamp":1489449600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1"},{"start":{"date-parts":[[2017,3,14]],"date-time":"2017-03-14T00:00:00Z","timestamp":1489449600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions"}],"funder":[{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Centers for Therapeutic Innovation"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Br J Dermatol"],"published-print":{"date-parts":[[2017,5]]},"DOI":"10.1111\/bjd.15006","type":"journal-article","created":{"date-parts":[[2016,8,26]],"date-time":"2016-08-26T10:27:44Z","timestamp":1472207264000},"page":"1224-1230","source":"Crossref","is-referenced-by-count":155,"title":["Correlation of cutaneous disease activity with type 1 interferon gene signature and interferon \u03b2 in dermatomyositis"],"prefix":"10.1093","volume":"176","author":[{"given":"C.","family":"Huard","sequence":"first","affiliation":[{"name":"Pfizer Inc.; Centers for Therapeutic Innovation; Boston MA U.S.A"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.V.","family":"Gull\u00e0","sequence":"additional","affiliation":[{"name":"Pfizer Inc.; Centers for Therapeutic Innovation; Boston MA U.S.A"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.V.","family":"Bennett","sequence":"additional","affiliation":[{"name":"Pfizer Inc.; Pharma Therapeutics; Precision Medicine; Cambridge MA U.S.A"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.J.","family":"Coyle","sequence":"additional","affiliation":[{"name":"Pfizer Inc.; Centers for Therapeutic Innovation; Boston MA U.S.A"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.A.","family":"Vleugels","sequence":"additional","affiliation":[{"name":"Department of Dermatology; Brigham and Women's Hospital; Boston MA U.S.A"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.A.","family":"Greenberg","sequence":"additional","affiliation":[{"name":"Department of Neurology; Brigham and Women's Hospital; Harvard Medical School; Boston MA U.S.A"},{"name":"Children's Hospital Informatics Program; Boston Children's Hospital; Boston MA U.S.A"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2017,3,14]]},"reference":[{"key":"10.1111\/bjd.15006-BIB0001|bjd15006-cit-0001","doi-asserted-by":"crossref","first-page":"4154","DOI":"10.4049\/jimmunol.168.8.4154","article-title":"Gene expression profiling in DQA1*0501 + children with untreated dermatomyositis: a novel model of pathogenesis","volume":"168","author":"Tezak","year":"2002","journal-title":"J Immunol"},{"key":"10.1111\/bjd.15006-BIB0002|bjd15006-cit-0002","doi-asserted-by":"crossref","first-page":"1170","DOI":"10.1212\/WNL.59.8.1170","article-title":"Molecular profiles of inflammatory myopathies","volume":"59","author":"Greenberg","year":"2002","journal-title":"Neurology"},{"key":"10.1111\/bjd.15006-BIB0003|bjd15006-cit-0003","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1002\/ana.20464","article-title":"Interferon-alpha\/beta-mediated innate immune mechanisms in dermatomyositis","volume":"57","author":"Greenberg","year":"2005","journal-title":"Ann Neurol"},{"key":"10.1111\/bjd.15006-BIB0004|bjd15006-cit-0004","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1002\/ana.21805","article-title":"Interferon-stimulated gene 15 (ISG15) conjugates proteins in dermatomyositis muscle with perifascicular atrophy","volume":"67","author":"Salajegheh","year":"2010","journal-title":"Ann Neurol"},{"key":"10.1111\/bjd.15006-BIB0005|bjd15006-cit-0005","doi-asserted-by":"crossref","first-page":"2079","DOI":"10.1212\/WNL.0b013e31821f440a","article-title":"Type I interferon and Toll-like receptor expression characterizes inflammatory myopathies","volume":"76","author":"Cappelletti","year":"2011","journal-title":"Neurology"},{"key":"10.1111\/bjd.15006-BIB0006|bjd15006-cit-0006","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1002\/path.4346","article-title":"Altered RIG-I\/DDX58-mediated innate immunity in dermatomyositis","volume":"233","author":"Suarez-Calvet","year":"2014","journal-title":"J Pathol"},{"key":"10.1111\/bjd.15006-BIB0007|bjd15006-cit-0007","doi-asserted-by":"crossref","first-page":"3784","DOI":"10.1002\/art.22928","article-title":"Type I interferon-inducible gene expression in blood is present and reflects disease activity in dermatomyositis and polymyositis","volume":"56","author":"Walsh","year":"2007","journal-title":"Arthritis Rheum"},{"key":"10.1111\/bjd.15006-BIB0008|bjd15006-cit-0008","doi-asserted-by":"crossref","first-page":"e29161","DOI":"10.1371\/journal.pone.0029161","article-title":"Interferon and biologic signatures in dermatomyositis skin: specificity and heterogeneity across diseases","volume":"7","author":"Wong","year":"2012","journal-title":"PLOS ONE"},{"key":"10.1111\/bjd.15006-BIB0009|bjd15006-cit-0009","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1038\/gene.2011.61","article-title":"Relationship between disease activity and type 1 interferon- and other cytokine-inducible gene expression in blood in dermatomyositis and polymyositis","volume":"13","author":"Greenberg","year":"2012","journal-title":"Genes Immun"},{"key":"10.1111\/bjd.15006-BIB0010|bjd15006-cit-0010","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1136\/annrheumdis-2012-202794","article-title":"A phase 1b clinical trial evaluating sifalimumab, an anti-IFN-\u03b1 monoclonal antibody, shows target neutralisation of a type I IFN signature in blood of dermatomyositis and polymyositis patients","volume":"73","author":"Higgs","year":"2014","journal-title":"Ann Rheum Dis"},{"key":"10.1111\/bjd.15006-BIB0011|bjd15006-cit-0011","doi-asserted-by":"crossref","first-page":"1785","DOI":"10.1002\/art.24557","article-title":"Neutralization of interferon-alpha\/beta-inducible genes and downstream effect in a phase I trial of an anti-interferon-alpha monoclonal antibody in systemic lupus erythematosus","volume":"60","author":"Yao","year":"2009","journal-title":"Arthritis Rheum"},{"key":"10.1111\/bjd.15006-BIB0012|bjd15006-cit-0012","doi-asserted-by":"crossref","first-page":"1905","DOI":"10.1136\/ard.2010.144485","article-title":"Safety profile and clinical activity of sifalimumab, a fully human anti-interferon alpha monoclonal antibody, in systemic lupus erythematosus: a phase I, multicentre, double-blind randomised study","volume":"70","author":"Merrill","year":"2011","journal-title":"Ann Rheum Dis"},{"key":"10.1111\/bjd.15006-BIB0013|bjd15006-cit-0013","doi-asserted-by":"crossref","first-page":"3666","DOI":"10.1002\/art.34632","article-title":"Safety and pharmacodynamics of rontalizumab in patients with systemic lupus erythematosus: results of a phase I, placebo-controlled, double-blind, dose-escalation study","volume":"64","author":"McBride","year":"2012","journal-title":"Arthritis Rheum"},{"key":"10.1111\/bjd.15006-BIB0014|bjd15006-cit-0014","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1002\/art.37824","article-title":"Sifalimumab, a human anti-interferon-alpha monoclonal antibody, in systemic lupus erythematosus: a phase I randomized, controlled, dose-escalation study","volume":"65","author":"Petri","year":"2013","journal-title":"Arthritis Rheum"},{"key":"10.1111\/bjd.15006-BIB0015|bjd15006-cit-0015","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1111\/j.1756-185X.2012.01764.x","article-title":"Biomarkers for systemic lupus erythematosus","volume":"15","author":"Herbst","year":"2012","journal-title":"Int J Rheum Dis"},{"issue":"Suppl. 1","key":"10.1111\/bjd.15006-BIB0016|bjd15006-cit-0016","doi-asserted-by":"crossref","first-page":"S6","DOI":"10.1186\/ar2887","article-title":"Use of type I interferon-inducible mRNAs as pharmacodynamic markers and potential diagnostic markers in trials with sifalimumab, an anti-IFN\u03b1 antibody, in systemic lupus erythematosus","volume":"12","author":"Yao","year":"2010","journal-title":"Arthritis Res Ther"},{"key":"10.1111\/bjd.15006-BIB0017|bjd15006-cit-0017","doi-asserted-by":"crossref","first-page":"887","DOI":"10.1111\/j.1365-2133.2008.08711.x","article-title":"Comparison of the reliability and validity of outcome instruments for cutaneous dermatomyositis","volume":"159","author":"Klein","year":"2008","journal-title":"Br J Dermatol"},{"key":"10.1111\/bjd.15006-BIB0018|bjd15006-cit-0018","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1111\/j.1365-2133.2009.09521.x","article-title":"Modification of the cutaneous dermatomyositis disease area and severity index, an outcome instrument","volume":"162","author":"Yassaee","year":"2010","journal-title":"Br J Dermatol"},{"key":"10.1111\/bjd.15006-BIB0019|bjd15006-cit-0019","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1038\/jid.2011.440","article-title":"Evaluation of reliability, validity, and responsiveness of the CDASI and the CAT-BM","volume":"132","author":"Goreshi","year":"2012","journal-title":"J Invest Dermatol"},{"key":"10.1111\/bjd.15006-BIB0020|bjd15006-cit-0020","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1111\/bjd.13915","article-title":"Validation of the Cutaneous Dermatomyositis Disease Area and Severity Index: characterizing disease severity and assessing responsiveness to clinical change","volume":"173","author":"Anyanwu","year":"2015","journal-title":"Br J Dermatol"},{"key":"10.1111\/bjd.15006-BIB0021|bjd15006-cit-0021","unstructured":"Babraham Bioinformatics http:\/\/www.bioinformatics.bbsrc.ac.uk\/projects\/fastqc\/"},{"key":"10.1111\/bjd.15006-BIB0022|bjd15006-cit-0022","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1093\/bioinformatics\/bts635","article-title":"STAR: ultrafast universal RNA-seq aligner","volume":"29","author":"Dobin","year":"2013","journal-title":"Bioinformatics"},{"key":"10.1111\/bjd.15006-BIB0023|bjd15006-cit-0023","doi-asserted-by":"crossref","first-page":"1760","DOI":"10.1101\/gr.135350.111","article-title":"GENCODE: the reference human genome annotation for the ENCODE Project","volume":"22","author":"Harrow","year":"2012","journal-title":"Genome Res"},{"key":"10.1111\/bjd.15006-BIB0024|bjd15006-cit-0024","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1038\/nbt.2931","article-title":"Normalization of RNA-seq data using factor analysis of control genes or samples","volume":"32","author":"Risso","year":"2014","journal-title":"Nat Biotechnol"},{"key":"10.1111\/bjd.15006-BIB0025|bjd15006-cit-0025","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1089\/107999099314171","article-title":"Correlation of interferon-induced expression of MxA mRNA in peripheral blood mononuclear cells with the response of patients with chronic active hepatitis C to IFN-alpha therapy","volume":"19","author":"Antonelli","year":"1999","journal-title":"J Interferon Cytokine Res"},{"key":"10.1111\/bjd.15006-BIB0026|bjd15006-cit-0026","doi-asserted-by":"crossref","first-page":"3770","DOI":"10.1128\/AAC.49.9.3770-3775.2005","article-title":"Quantification of different human alpha interferon subtypes and pegylated interferon activities by measuring MxA promoter activation","volume":"49","author":"Francois","year":"2005","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1111\/bjd.15006-BIB0027|bjd15006-cit-0027","doi-asserted-by":"crossref","first-page":"1663","DOI":"10.4049\/jimmunol.173.3.1663","article-title":"IFN-alpha subtypes differentially affect human T cell motility","volume":"173","author":"Foster","year":"2004","journal-title":"J Immunol"},{"key":"10.1111\/bjd.15006-BIB0028|bjd15006-cit-0028","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1089\/jir.2007.0142","article-title":"Quantification of neutralizing antibodies to human type I interferons using division-arrested frozen cells carrying an interferon-regulated reporter-gene","volume":"28","author":"Lallemand","year":"2008","journal-title":"J Interferon Cytokine Res"},{"key":"10.1111\/bjd.15006-BIB0029|bjd15006-cit-0029","doi-asserted-by":"crossref","first-page":"4078","DOI":"10.1002\/art.34659","article-title":"Changes in novel biomarkers of disease activity in juvenile and adult dermatomyositis are sensitive biomarkers of disease course","volume":"64","author":"Reed","year":"2012","journal-title":"Arthritis Rheum"},{"key":"10.1111\/bjd.15006-BIB0030|bjd15006-cit-0030","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1136\/ard.2010.139949","article-title":"Interferon beta is associated with type 1 interferon-inducible gene expression in dermatomyositis","volume":"70","author":"Liao","year":"2011","journal-title":"Ann Rheum Dis"},{"key":"10.1111\/bjd.15006-BIB0031|bjd15006-cit-0031","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1093\/rheumatology\/keg427","article-title":"International consensus outcome measures for patients with idiopathic inflammatory myopathies. Development and initial validation of myositis activity and damage indices in patients with adult onset disease","volume":"43","author":"Isenberg","year":"2004","journal-title":"Rheumatology (Oxford)"},{"key":"10.1111\/bjd.15006-BIB0032|bjd15006-cit-0032","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1016\/j.jaad.2004.12.015","article-title":"Cutaneous symptoms of dermatomyositis significantly impact patients\u2019 quality of life","volume":"54","author":"Hundley","year":"2006","journal-title":"J Am Acad Dermatol"},{"key":"10.1111\/bjd.15006-BIB0033|bjd15006-cit-0033","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1016\/j.jaad.2010.10.016","article-title":"Quality of life in dermatomyositis","volume":"65","author":"Goreshi","year":"2011","journal-title":"J Am Acad Dermatol"},{"key":"10.1111\/bjd.15006-BIB0034|bjd15006-cit-0034","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1111\/bjd.13167","article-title":"Improvement in the cutaneous disease activity of patients with dermatomyositis is associated with a better quality of life","volume":"172","author":"Robinson","year":"2015","journal-title":"Br J Dermatol"}],"container-title":["British Journal of Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fbjd.15006","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fbjd.15006","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/onlinelibrary.wiley.com\/wol1\/doi\/10.1111\/bjd.15006\/fullpdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,2,14]],"date-time":"2023-02-14T09:23:16Z","timestamp":1676366596000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/bjd\/article\/176\/5\/1224\/6661087"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,3,14]]},"references-count":34,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2017,5]]}},"URL":"https:\/\/doi.org\/10.1111\/bjd.15006","archive":["Portico"],"relation":{},"ISSN":["0007-0963"],"issn-type":[{"value":"0007-0963","type":"print"}],"subject":[],"published":{"date-parts":[[2017,3,14]]}}}